Advanced stage Hodgkinʼs lymphoma 2024—Update on first line treatment

2024-9-13

Importance of genetic clarification in cytopenia syndromes (childhood myelodysplastic syndrome forms)

2024-8-29

A GLOBAL CONGRESS DIGEST ON TARGETED THERAPIES IN B-CELL MALIGNANCIES Report from the European Hematology Association (EHA) 2024 Congress (hybrid), 13th – 16th June 2024

2024-8-26

Acute lymphoblastic leukemia at the 2023 ASH meeting

2024-8-22

KRAS (Kirsten rat sarcoma) in modern oncology—The molecular pathological point of view

2024-8-21

Importance of allogeneic stem cell transplantation in myelofibrosis

2024-8-12

Trends in MDS and AML from ASH 2023

2024-7-18

Novel mutated Dubin–Johnson syndrome diagnosed during acute promyelocytic leukemia treatment

2024-7-11

Updates and changes in the treatment of cervical cancer

2024-6-20

Antibody–drug conjugates (ADCs) in lung cancer treatment

2024-6-6

GATA2 deficiency: a mystery myelodysplasia

2024-6-5

Emerging drugs in breast cancer: a focus on antibody–drug conjugates and novel treatment options in luminal disease

2024-6-4

Liquid profiling for patients with advanced cancer is ready for clinical integration

2024-5-16

Antibody–drug conjugates in the treatment of lymphoid neoplasms

2024-5-1

Rare lung cancer special: a multifaceted approach

2024-5-1

Antibody–drug conjugates (ADC special)—part 1

2024-5-1

Congress update 2023—ASCO and ESMO

2024-5-1

The molecular tumor board—a key element of precision oncology

2024-4-30

NEC versus NET G3—is there a grey zone? Case report of pancreatic NET G3 with rapid disease progression

2024-4-29

Liquid biopsy in breast cancer

2024-4-23

Alternating chemotherapy with VDC-IE as effective first-line treatment in a patient with SMARCA4-deficient undifferentiated tumor

2024-4-22

The future of clinical trials—goals, ideas, and discussion

2024-4-18

American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia

2024-4-18

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

2024-3-26

Treatment-changing news in urogenital cancer—a brief unstructured narrative review based on findings presented at the ESMO 2023 conference

2024-3-18

Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology

2024-3-13

Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma

2024-2-28

Seminal vesicle metastasis from transverse colon adenocarcinoma: a unique case report

2024-2-23

β-adrenergic modulation of IL-6/gp130 and SOCS-1 in multiple myeloma: therapeutic strategy for stress induced-inflammatory response

2024-2-9

Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations

2024-2-8

OeGHO annual meeting 2023—best of oncology

2024-2-1

Prostate cancer special—part 2

2024-2-1

“Navigating the evolving landscape of cancer treatment: a triad of progress”

2024-2-1

Innovative therapeutic concepts for biliary tumors

2024-1-29

Can artificial intelligence provide accurate and reliable answers to cancer patients’ questions about cancer pain? Comparison of chatbots based on ESMO cancer pain guideline

2024-1-26

Antibody–drug conjugates in ovarian cancer

2024-1-25

Acute myeloid leukemia patient with active disseminated tuberculosis bridged to transplant with reduced 14-day venetoclax and azacitidine schedule

2024-1-23

(Neo)adjuvant approaches in lung cancer—paving the road to a cure

2024-1-19

Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review

2024-1-16

Pulmonary puzzles: salivary gland-type tumors of the lung and their metastatic equivalents

2024-1-11

Transformation of epidermal growth factor receptor-mutated non-small cell lung cancer into small cell lung cancer—case report

2024-1-8

Molecular typing—new targets and therapy options for upper GI carcinomas with a focus on adenocarcinomas of the esophagus, gastroesophageal junction, and stomach

2024-1-5

Metastasis-directed therapy: new standard or too early to change paradigm?

2023-12-29

Upper-GI highlights from ASCO and ASCO-GI 2023 meetings: changing paradigm in treatment sequence

2023-12-29

Total neoadjuvant therapy for each local advanced rectal cancer?

2023-12-28

(Neo)adjuvant approaches: pavement on the road to cure—breast cancer

2023-12-19

Diagnosis and management of mediastinal extragonadal germ cell tumors

2023-12-18

Management of oligometastatic prostate cancer

2023-12-18

ASCO 2023: highlights in breast cancer

2023-12-5

Cancer of unknown primary—state of the art

2023-12-5